- Home
- REPL vs KREF Comparison
REPL vs KREF Comparison
Compare REPL & KREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- KREF
- Stock Information
- Founded
- REPL 2015
- KREF 2014
- Country
- REPL United States
- KREF United States
- Employees
- REPL N/A
- KREF N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- KREF Real Estate Investment Trusts
- Sector
- REPL Health Care
- KREF Real Estate
- Exchange
- REPL Nasdaq
- KREF Nasdaq
- Market Cap
- REPL 547.0M
- KREF 623.9M
- IPO Year
- REPL 2018
- KREF 2017
- Fundamental
- Price
- REPL $9.42
- KREF $8.35
- Analyst Decision
- REPL Buy
- KREF Buy
- Analyst Count
- REPL 9
- KREF 6
- Target Price
- REPL $12.00
- KREF $10.71
- AVG Volume (30 Days)
- REPL 2.6M
- KREF 890.9K
- Earning Date
- REPL 11-06-2025
- KREF 10-21-2025
- Dividend Yield
- REPL N/A
- KREF 12.32%
- EPS Growth
- REPL N/A
- KREF N/A
- EPS
- REPL N/A
- KREF N/A
- Revenue
- REPL N/A
- KREF $62,012,000.00
- Revenue This Year
- REPL N/A
- KREF $16.86
- Revenue Next Year
- REPL N/A
- KREF N/A
- P/E Ratio
- REPL N/A
- KREF N/A
- Revenue Growth
- REPL N/A
- KREF N/A
- 52 Week Low
- REPL $2.68
- KREF $7.78
- 52 Week High
- REPL $17.00
- KREF $11.85
- Technical
- Relative Strength Index (RSI)
- REPL 62.38
- KREF 50.26
- Support Level
- REPL $8.50
- KREF $8.04
- Resistance Level
- REPL $9.30
- KREF $8.36
- Average True Range (ATR)
- REPL 0.61
- KREF 0.20
- MACD
- REPL -0.14
- KREF 0.04
- Stochastic Oscillator
- REPL 75.95
- KREF 88.45
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.